Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target

In Q3 2025, Biomea announced that the institution was shifting its strategy to absorption connected its 2 superior assets: icovamenib, a menin inhibitor for benignant 2 diabetes/T2D, and BMF-650, an oral GLP-1 receptor agonist for obesity. Icovamenib is an oral tiny molecule designed to partially inhibit menin, a macromolecule that acts arsenic a brake connected pancreatic beta-cell growth. By inhibiting menin, the therapy aims to regenerate and reactivate healthy, insulin-producing beta cells, perchance offering a disease-modifying attraction for diabetes alternatively than conscionable managing symptoms.

During the quarter, Biomea Fusion Inc. (NASDAQ:BMEA) reported durable 52-week information from its Phase II COVALENT-111 study. In patients with terrible insulin-deficient T2D, a abbreviated 12-week people of icovamenib resulted successful a sustained 1.5% mean simplification successful HbA1c 9 months aft dosing ended. Additionally, patients who had failed to scope glycemic targets connected GLP-1 therapies saw a 1.3% simplification successful HbA1c. These results are peculiarly notable due to the fact that they suggest a bequest effect wherever benefits proceed agelong aft the medicine is stopped.

Biomea Fusion Inc. (NASDAQ:BMEA) is simply a clinical-stage diabetes and obesity medicines institution that discovers and develops oral covalent tiny molecule drugs to dainty patients with metabolic diseases successful the US.

While we admit the imaginable of BMEA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.